Adocia
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Nov 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 2 to 25, 2027 · next Jan 2
- 1 fee due Feb 20, 2027The maintenance fee for Injectable solution at pH 7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals (US 10,383,920) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
- 1 fee due May 5, 2027The maintenance fee for Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid (US 10,463,717) comes due May 5, 2027. Unpaid by Nov 5, 2027, it lapses early.
- 1 fee due Jun 1, 2027The maintenance fee for Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid (US 9,198,971) comes due Jun 1, 2027. Unpaid by Dec 1, 2027, it lapses early.
- 1 fee due Jul 30, 2027The maintenance fee for Injectable PH 7 Solution Comprising at Least One Basal Insulin Having a Pi from 5.8 to 8.5 and a Co-Polyamino Acid Bearing Carboxylate Charges and Hydrophobic Radicals (US 11,883,496) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.
- 1 fee due Aug 4, 2027The maintenance fee for Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals (US 10,548,952) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
- 2 fees due Sep 8 to 10, 2027 · next Sep 8
- 1 fee due Oct 7, 2027The maintenance fee for Compositions in the Form of an Injectable Aqueous Solution Including at Least Human Insulin A21G and a Glucagon Suppressor with Prandial Action (US 10,610,572) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.
- 1 fee due Nov 12, 2027The maintenance fee for Rapid-acting insulin formulation comprising a substituted anionic compound (US 10,646,551) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,492,467 | Rapid-acting insulin formulation comprising an oligosaccharide In force · USPTO record | In force | USPTO record | |
| US 9,018,190 | Functionalized oligosaccharides In force · USPTO record | In force | USPTO record | |
| US 9,198,971 | Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid In force · USPTO record | In force | USPTO record | |
| US 10,335,489 | Injectable solution at pH 7 comprising at least one basal insulin the pi of which is between 5.8 and 8.5 and a substituted co-polyamino acid In force · USPTO record | In force | USPTO record | |
| US 10,583,175 | Rapid-acting insulin formulation comprising a substituted anionic compound In force · USPTO record | In force | USPTO record | |
| US 10,646,551 | Rapid-acting insulin formulation comprising a substituted anionic compound In force · USPTO record | In force | USPTO record | |
| US 10,881,716 | Rapid-acting insulin formulation comprising a substituted anionic compound In force · USPTO record | In force | USPTO record | |
| US 11,324,808 | Rapid-acting insulin formulation comprising a substituted anionic compound In force · USPTO record | In force | USPTO record | |
| US 9,493,583 | Anionic polysaccharides functionalized by a hydrophobic acid derivative In force · USPTO record | In force | USPTO record | |
| US 9,278,131 | Process for lowering the viscosity of highly concentrated protein solutions In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 29: 14 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 1 abandoned · 47 no status recorded
Showing 1 to 10 of 52, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/970,153 | Dec 5, 2024 | No status recorded | |
| 18/963,911 | Compositions in the Form of an Injectable Aqueous Solution Comprising Amylin, an Amylin Agonist Receptor or an Amylin Analogue and a Co-Polyamino Acid | Nov 29, 2024 | Pending |
| 18/370,720 | Compositions Comprising at Least an Insulin and an Amylin Receptor Agonist for Treating Diabetes, in a Patient/Person Having a Bmi of More Than 28 KG/M² And/Or an HBA1C of More Than 7.6% | Sep 20, 2023 | Pending |
| 18/879,641 | Compositions Comprising a Peptide or a Protein and an Acylated Amino Acid | Jun 30, 2023 | Pending |
| 18/709,636 | Solid Compositions Comprising a Peptide or a Protein and an Acylated Amino Acid | Nov 15, 2022 | Pending |
| 17/404,547 | Aug 17, 2021 | No status recorded | |
| 17/400,617 | Aug 12, 2021 | No status recorded | |
| 17/928,502 | May 28, 2021 | No status recorded | |
| 17/928,434 | May 28, 2021 | No status recorded | |
| 17/208,514 | Mar 22, 2021 | No status recorded |
10 of 52 applications shown.
Pro members see all 52 published applications.